Topical STAT3 inhibition is associated with severe vaccinia disease and dermatitis in CTX treated FT mice. Yong He Ishrat Sultana Kazuyo Takeda Jennifer L. Reed 10.1371/journal.pone.0170070.g002 https://plos.figshare.com/articles/figure/Topical_STAT3_inhibition_is_associated_with_severe_vaccinia_disease_and_dermatitis_in_CTX_treated_FT_mice_/4550020 <p>A) Schematic protocol. The STAT3 specific inhibitor Stattic® was applied topically for two weeks before ACAM-2000 scarification in CTX treated FT mice. Animals received VIG or vehicle control on days 2, 5, 10 and 15. B) Rapidly progressing vaccinia disease was significantly delayed by VIG (n = 9–10). C) Representative uninfected (left) and infected (right) mice. D) Virus recovery from primary lesions on day 20 (n = 5 per group). Viral burden in skin was significantly reduced in VIG recipients. Representative data from 2 experiments are shown.</p> 2017-01-12 17:42:57 novel co-therapeutic approach ACAM -2000 infection limit weight loss VIG Vivo Rationale Defects filaggrin limit cutaneous spread ALK cutaneous pathogen persistence TGF STAT 3 Exacerbates Vaccinia Disease AD skin infection vaccinia